Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Sep;94(9):802-8.
doi: 10.1111/j.1349-7006.2003.tb01522.x.

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide

Yuji Sato  1 , Hiroki Shomura, Yoshiaki Maeda, Takashi Mine, Yoshie Une, Yoshinobu Akasaka, Masao Kondo, Shusaku Takahashi, Toshiki Shinohara, Kazuko Katagiri, Mika Sato, Shiori Okada, Kanae Matsui, Akira Yamada, Hideaki Yamana, Kyogo Itoh, Satoru Todo
Affiliations
Clinical Trial

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide

Yuji Sato et al. Cancer Sci. 2003 Sep.

Abstract

There is no standard treatment modality for advanced gastric cancer (GC) at the present time. To develop a new treatment modality, we investigated the immunological responses of advanced GC patients (n = 13, 9 non-scirrhous and 4 scirrhous types) vaccinated with peptides to a regimen under which pre-vaccination peripheral blood mononuclear cells (PBMCs) were screened for their reactivity in vitro to each of 14 peptides on HLA-A24 or 16 peptides on -A2 allele, then only the reactive peptides (maximum: 4) were administered in vivo. This regimen was generally well tolerated, although grade I levels of fever and local skin reactions were observed in several patients. Delayed-type hypersensitivity (DTH) to the vaccinated peptides was observed in 4 patients. Increased cellular and humoral immune responses to the vaccinated peptides were observed in post-vaccination PBMCs from 4 of 8 patients and in post-vaccination sera of 8 of 10 patients tested, respectively. Prolonged survival was observed in patients showing cellular and humoral immune responses to the vaccinated peptides in the post-vaccination samples, including all 4 patients with the scirrhous type. These results encourage further development of peptide-based immunotherapy for GC patients.

PubMed Disclaimer

References

    1. Karpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles' practice of oncology. 6th ed. Philadelphia : Lippincott Williams' Wilkins; 2001. p. 1092–121.
    1. Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K, Saku M. Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol 1995; 58: 112–7. - PubMed
    1. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 277–88. - PMC - PubMed
    1. Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Itoh K. Molecular basis of T cell‐mediated recognition of pancreatic cancer cells. Cancer Res 2001; 61: 2038–46. - PubMed
    1. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA‐A24‐restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056–63. - PubMed

MeSH terms